Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 3/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | SCTR | P47872 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12603082 | 0.87 | ERBB2 (0.39) | PSMB5RENPTPN1ERBB2CALCRL | |
| SCHEMBL2742710 | 0.85 | CALCRL (0.37) | CASP3PTPN1ERBB2CALCRLCASP7 | |
| SCHEMBL12873177 | 0.85 | CALCRL (0.37) | CASP3PTPN1ERBB2CALCRLCASP7 | |
| SCHEMBL29961965 | 0.83 | CALCRL (0.37) | ERBB2CALCRL | |
| SCHEMBL30009160 | 0.81 | CALCRL (0.48) | CASP3CALCRLCASP7 | |
| SCHEMBL21766737 | 0.79 | MAGI3 (0.39) | PTPN1KEAP1 | |
| SCHEMBL21766784 | 0.77 | ERAP2 (0.37) | PTPN1ERBB2KEAP1 | |
| SCHEMBL21766769 | 0.77 | SYK (0.41) | GLP1RSCTRIL23R | |
| SCHEMBL30788325 | 0.77 | BACE1 (0.38) | CASP3CASP7 | |
| SCHEMBL30632044 | 0.76 | PTPN1 (0.39) | CASP3PTPN1CASP7KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10994017-B2 | Nerve labeling compositions and uses thereof | AVELAS BIOSCIENCES, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200061200-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | AVELAS ACQUISITION CORPORATION | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061200-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | GAP43, NGF, PMP22 | PSMB5 2101/4885CASP3 1654/4885REN 3034/4885 |
| US-10994017-B2 | Nerve labeling compositions and uses thereof | GAP43, NGF, PMP22 | PSMB5 2101/4885CASP3 1654/4885REN 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.